STOCK TITAN

Alx Oncology Holdings Inc - ALXO STOCK NEWS

Welcome to our dedicated page for Alx Oncology Holdings news (Ticker: ALXO), a resource for investors and traders seeking the latest updates and insights on Alx Oncology Holdings stock.

Overview

ALX Oncology Holdings Inc (NASDAQ: ALXO) is a clinical‐stage biotechnology company dedicated to advancing innovative immuno‐oncology therapies. With a deep expertise in protein engineering, ALX Oncology is focused on developing treatments that block the CD47 immune checkpoint—a mechanism by which cancer cells signal the immune system not to attack. This approach is particularly significant in the context of enhancing both the innate and adaptive immune responses against malignancies. Keywords such as immuno‐oncology, CD47 blockade, and checkpoint inhibitor are central to the company’s identity and strategic direction.

Core Technology and Therapeutic Approach

The company’s lead product candidate, evorpacept, is a fusion protein that integrates an engineered, high-affinity CD47 binding domain with an inactivated Fc region, designed to minimize hematologic toxicities common to other CD47 blocking agents. This strategic design not only optimizes safety but also allows for potentially higher dosing in combination regimens. By mitigating the "don't eat me" signal of CD47, the therapy aims to restore the immune system’s ability to recognize and eliminate cancer cells. This precision in molecular design underlines ALX Oncology’s commitment to developing next-generation immunotherapies.

Clinical Development and Research Focus

ALX Oncology has built a robust clinical-stage pipeline that explores various combination strategies, investigating evorpacept with established anti-cancer antibodies, ADCs, and checkpoint inhibitors. The company conducts multiple studies across hematologic and solid malignancies, using its therapeutic candidate as a combinatorial partner to address complex cancer pathologies. While avoiding specific numerical data and time-sensitive details, it is evident that the clinical program is designed with a strong emphasis on advanced safety profiles and meaningful anti-tumor activity.

Market Position and Competitive Differentiation

Within the competitive landscape of immunotherapies, ALX Oncology differentiates itself through its innovative approach to CD47 blockade. Unlike competitors using active Fc domains, evorpacept employs an inactivated Fc region to reduce overlapping toxicities, potentially allowing effective higher dosing when used in combination with other therapies. This nuanced approach not only enhances its safety profile but also positions the company as an important contributor to evolving cancer treatment paradigms. The company’s strategic focus on combination therapies reflects a broader industry trend, wherein multi-modality treatment regimens are increasingly recognized for their potential to overcome resistance mechanisms in cancer cells.

Scientific and Clinical Expertise

ALX Oncology’s efforts are supported by a team with extensive experience in oncology, immunology, and biopharmaceutical research. The company integrates cutting-edge scientific advancements with clinical insights to drive its development programs. The rigorous, data-driven approach in its clinical trials underscores a commitment to high standards of scientific inquiry and patient safety. Moreover, the use of rational design principles in developing evorpacept demonstrates the company’s methodical and evidence-based approach to overcoming conventional therapeutic limitations.

Strategic Focus

The company remains focused on enhancing therapeutic outcomes by leveraging its product pipeline to bridge innate and adaptive immunity. Through collaborations and combination studies, ALX Oncology aims to address complex oncologic challenges while ensuring that its therapies maintain a broad applicability across multiple cancer indications. Each study is designed to provide insights into treatment efficacy and safety, contributing to an evolving landscape of immuno-oncology research that emphasizes precision, tolerability, and synergistic potential with other anti-cancer modalities.

Conclusion

In summary, ALX Oncology Holdings Inc. embodies a forward-thinking approach in the realm of immuno-oncology by targeting the CD47 checkpoint with a uniquely engineered candidate. The company’s integration of advanced protein design, strong clinical trial data, and a focus on combinational therapies places it in a notable position within the competitive biotechnology sector. This comprehensive approach not only highlights its scientific and clinical rigor but also provides a clear understanding of its business model and market significance for investors and industry observers alike.

Rhea-AI Summary

ALX Oncology Holdings Inc. (Nasdaq: ALXO) provided an update on its clinical progress and corporate milestones for 2023. The company is advancing its lead candidate, evorpacept, in several cancer indications, including a Phase 1 trial in urothelial cancer and trials in combination therapies for colorectal and breast cancer. Key accomplishments from 2022 include regulatory designations and financial support through a $100 million loan facility. ALX Oncology expects to present pivotal data in 2023, aiming for continued growth in clinical development.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.09%
Tags
none
-
Rhea-AI Summary

ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage immuno-oncology company, will be presenting at the 41st Annual J.P. Morgan Healthcare Conference on January 10, 2023, at 10:30 am PT. CEO Jaume Pons, Ph.D., will provide a company overview at the event taking place in San Francisco.

A live webcast of the presentation will be accessible through ALX Oncology's website, and a replay will be available for 30 days post-event. The company focuses on developing therapies that block the CD47 checkpoint pathway, with their lead candidate, evorpacept, showing promise in treating various cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
conferences
-
Rhea-AI Summary

ALX Oncology (Nasdaq: ALXO) announced promising clinical data from the Phase 1a dose escalation of the ASPEN-05 trial, evaluating evorpacept in combination with azacitidine and venetoclax for acute myeloid leukemia (AML). The treatment showed antileukemic activity in patients with both relapsed/refractory and newly diagnosed AML, with responses observed among 10 r/r patients and all 3 newly diagnosed patients. Notably, no evorpacept-related cytopenias were reported. A conference call is scheduled for December 13, 2022 to discuss these findings.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
5.12%
Tags
none
Rhea-AI Summary

ALX Oncology Holdings Inc. (Nasdaq: ALXO) announced the appointment of Scott Garland to its Board of Directors, effective November 29, 2022. With over 30 years in the biopharmaceutical industry, Garland brings significant commercial and executive experience. As CEO of PACT Pharma and former CEO of Portola Pharmaceuticals, he has led successful product launches and has deep expertise in immuno-oncology. This addition aims to enhance ALX's strategic direction, particularly in developing its lead candidate, evorpacept, a novel therapy for treating cancer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7.25%
Tags
management
-
Rhea-AI Summary

ALX Oncology (Nasdaq: ALXO) reported Q3 2022 financials, noting a GAAP net loss of $35.3 million, or $0.87 per share, versus $24.6 million, or $0.61 per share, in Q3 2021. R&D expenses rose to $29.4 million, driven by increased clinical trial costs. The company secured a non-dilutive loan facility to extend its cash runway to mid-2025, with $293.1 million in cash and equivalents as of September 30, 2022. Evorpacept's clinical development continues, including new treatment arms in the I-SPY-P1 TRIAL and ongoing trials for advanced colorectal cancer and head and neck squamous cell carcinoma.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.64%
Tags
-
Rhea-AI Summary

ALX Oncology Holdings Inc. (Nasdaq: ALXO) will present clinical data from the dose escalation portion of ASPEN-05, a Phase 1 study, at the 64th American Society of Hematology Annual Meeting from December 10-13, 2022. The study evaluates evorpacept in combination with azacitidine and venetoclax for treating acute myeloid leukemia (AML). The poster presentation is scheduled for December 12, 2022, highlighting promising clinical responses from evorpacept across various hematologic and solid malignancies.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-1.33%
Tags
conferences clinical trial
Rhea-AI Summary

ALX Oncology Holdings Inc. (Nasdaq: ALXO) is participating in four investor conferences to discuss its immuno-oncology therapies targeting the CD47 checkpoint pathway. Key events include the Credit Suisse 31st Annual Healthcare Conference on November 9, Stifel 2022 Healthcare Conference on November 15, Jefferies London Healthcare Conference on November 17, and Piper Sandler 34th Annual Healthcare Conference on November 29. The company is focused on the clinical development of its lead product candidate, evorpacept, aimed at treating various cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.62%
Tags
conferences
-
Rhea-AI Summary

ALX Oncology Holdings Inc. (ALXO) announced a loan agreement for up to $100 million of non-dilutive financing with Oxford Finance and Silicon Valley Bank. This funding will support the development of evorpacept, a CD47 blocking therapeutic. ALX has accessed $10 million of an initial $50 million tranche, with the remaining funds available at its discretion through 2023. The financing extends their cash runway to mid-2025, allowing for further clinical trials and milestones.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.96%
Tags
none
-
Rhea-AI Summary

ALX Oncology (Nasdaq: ALXO) announced the acceptance of two Trials in Progress abstracts for ASPEN-03 and ASPEN-04, Phase 2 studies on advanced head and neck cancer, at the SITC 37th Annual Meeting in Boston from November 8-12, 2022. The abstracts detail studies on evorpacept (ALX148) combined with pembrolizumab, with session times on November 10-11, 2022. ALX Oncology focuses on developing therapies that block the CD47 checkpoint pathway, with evorpacept showing promising results for various cancers.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.19%
Tags
none
Rhea-AI Summary

ALX Oncology Holdings Inc. (Nasdaq: ALXO), a clinical-stage immuno-oncology company, announced its participation in the Cantor Oncology, Hematology & HemeOnc Conference on September 28, 2022, in New York. CEO Jaume Pons, Ph.D., will be part of a moderated panel titled “Building Combinations: What are the Novel Ideas?” at 10:40 AM ET. Additionally, Dr. Pons and CFO Peter Garcia will conduct one-on-one investor meetings during the event. ALX Oncology is advancing its lead product candidate, evorpacept, aimed at treating various cancers by blocking the CD47 checkpoint pathway.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.38%
Tags
conferences

FAQ

What is the current stock price of Alx Oncology Holdings (ALXO)?

The current stock price of Alx Oncology Holdings (ALXO) is $0.5159 as of April 4, 2025.

What is the market cap of Alx Oncology Holdings (ALXO)?

The market cap of Alx Oncology Holdings (ALXO) is approximately 27.2M.

What is the core focus of ALX Oncology Holdings Inc.?

ALX Oncology is focused on developing innovative immuno-oncology therapies, particularly by targeting the CD47 immune checkpoint to help the immune system combat cancer.

How does evorpacept, the company’s lead candidate, work?

Evorpacept is a fusion protein that combines a high-affinity CD47 binding domain with an inactivated Fc region, designed to block the CD47 'don’t eat me' signal and enhance immune recognition of cancer cells.

What makes ALX Oncology’s approach to CD47 blockade unique?

The company’s approach uses an inactivated Fc domain to minimize hematologic toxicities, allowing for higher therapeutic dosing when used in combination with other anti-cancer agents.

In which areas is ALX Oncology conducting clinical studies?

ALX Oncology is engaged in clinical trials across various hematologic and solid malignancies, often exploring combination regimens with standard anticancer antibodies, ADCs, and checkpoint inhibitors.

How does ALX Oncology differentiate itself in the competitive immuno-oncology market?

ALX Oncology differentiates itself through its precise protein engineering, the unique safety profile of evorpacept, and its strategic focus on combination therapies that bridge innate and adaptive immunity.

What is the significance of targeting the CD47 checkpoint in cancer therapy?

Targeting the CD47 checkpoint is significant because it interrupts a key mechanism that cancer cells use to avoid immune detection, thereby potentially enhancing the efficacy of cancer treatments.

What role does combination therapy play in ALX Oncology’s research strategy?

Combination therapy is integral to their strategy as it aims to leverage the benefits of evorpacept alongside other anti-cancer agents, increasing therapeutic efficacy and addressing resistance mechanisms.

Who are the typical stakeholders interested in ALX Oncology’s developments?

Investors, clinicians, and researchers with an interest in cutting-edge immuno-oncology and targeted cancer therapies are the primary stakeholders following ALX Oncology’s clinical advancements.
Alx Oncology Holdings Inc

Nasdaq:ALXO

ALXO Rankings

ALXO Stock Data

27.22M
42.55M
2.03%
89.37%
11.03%
Biotechnology
Pharmaceutical Preparations
Link
United States
SOUTH SAN FRANCISCO